Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04540380 · ClinicalTrials.gov registry record · Phase 1
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
A Phase 1 study of Renal Failure, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04540380: Active Phase 1 study of Renal Failure, sponsored by Massachusetts General Hospital.
NCT04540380 is a Phase 1 study of Renal Failure that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 300-participant average among 11 other Renal Failure trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04540380, a Phase 1 study of Renal Failure, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Conditions Studied
Interventions
- DRUG Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab
- PROCEDURE Combined bone marrow and kidney transplant
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What the registry record for NCT04540380 still lists
NCT04540380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 300-participant average among 11 other Renal Failure trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Renal Failure appearing as the primary indexed condition, and to 2 interventions - of which Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab is the first listed.
NCT04540380 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04540380 about?
NCT04540380 is a clinical study titled "Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH". The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance...
What is the current status of trial NCT04540380?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-09-01. Estimated completion is 2027-06.
What conditions does trial NCT04540380 study?
This clinical trial studies the following conditions: Renal Failure.
What interventions are being tested in trial NCT04540380?
The interventions under investigation include: Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab (DRUG), Combined bone marrow and kidney transplant (PROCEDURE).
Who is sponsoring clinical trial NCT04540380?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04540380 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04540380's enrollment target sits among peer trials
20 8th of 11 higher than 2 of 11 other Renal Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post-Filter Hematocrit
RECRUITING · NA
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
RECRUITING · Early Phase 1
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure
COMPLETED · NA
-
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI